Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT01449461
Brief Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

First Submitted : September 30, 2011
First Submitted that Met QC Criteria : October 6, 2011
First Posted : October 10, 2011 (Estimate)

Results First Submitted : May 26, 2017
Results First Submitted that Met QC Criteria : May 26, 2017
Results First Posted : June 21, 2017

Last Update Submitted that Met QC Criteria : February 25, 2020
Last Update Posted : March 4, 2020